NCT00879879

Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: University of South Florida · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis. PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.

Detailed description

OBJECTIVES: * Evaluate the effects of losartan potassium on disease progression in patients with idiopathic pulmonary fibrosis. * Determine the safety of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive oral losartan potassium daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo pulmonary function tests with gas diffusion lung volumes, Carbon monoxide diffusing capacity (DLCO) tests, and 6-minute walk tests at baseline and then at 3, 6, 9, and 12 months. Patients also complete baseline/transition dyspnea index questionnaires at baseline and then at 1, 3, 6, 9, and 12 months.

Conditions

• Precancerous Condition

Interventions

Type	Name	Description
DRUG	losartan	50 mg losartan taken daily by mouth in capsule form for 1 year

Timeline

• Start date: 2009-03-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2009-04-13
• Last updated: 2021-02-21
• Results posted: 2013-10-14

Locations

1 site across 1 country: United States